Drug activity screens with potential anticancer compounds on the NCI‐60 cancer cell line panel revealed that many anticancer agents in clinical use, in particular DNA‐damaging agents, were more cytotoxic toward cells with an intact p53 pathway (O'Connor et al., 1997; Weinstein et al., 1997). The gene discussed is TP53; the disease is cancer.